RELX Releases Q3 2022 Performance Report on Nasdaq

Nov.17.2022
RELX Releases Q3 2022 Performance Report on Nasdaq
Relx's Q3 2022 report released on Nasdaq showed a 37.7% drop in net income, while gross margin increased by 10.9%.

On November 16 at 5 AM EST (November 16 at 4 PM Beijing Time), Yooz RELX (Huaxin Technology) released their 2022 Q3 financial performance report on NASDAQ. Here are the key takeaways gathered by 2FIRSTS.


In the third quarter of 2022, Yuke Technology reported a net income of 1.044 billion yuan, a 37.7% decrease from the same period last year, due primarily to paused store expansion and discontinued old products. The gross profit margin increased by 10.9% to 50% compared to the same period last year. Adjusted net income according to U.S. GAAP was 505.2 million yuan, a 48.4% decrease from the same period in the previous year. R&D investment saw a slight increase to 46 million yuan, compared to 44.6 million yuan in the same period last year. The company's cash and cash equivalents, restricted cash, short-term bank deposits, short-term investments, long-term bank deposits, net, and long-term investment securities totalled 16.405 billion yuan (approximately 2.306 billion USD) as of September 30, 2022, up from 14.72 billion yuan as of September 30, 2021. Yuke Technology is leading the way with its S&P CSA ESG score, which surpasses 67% of its peers globally. The company implemented cost control measures and reduced shipments of old products to adapt to new national standards and gradually shifted to a region-based national trading platform for complete national coverage. However, regulatory changes may lead to additional taxes and expenses, which could significantly impact profitability. As a result, there is significant uncertainty surrounding the company's future business performance. Cost control measures will remain a top strategic priority while maintaining sustainable long-term growth in the face of evolving regulatory environments.


Statement:


1. This article is intended for internal industry research and exchange only. It does not make any investment or brand recommendations. This article should not be used as a basis for investment decisions. 2. The data and analytical conclusions cited in this article have not been confirmed in writing with the companies. All data should be based on official publications from the companies.


This article is an original piece written by 2FIRSTS Technology Co., Ltd in Shenzhen. The copyright and permission for use are owned by the company and any unauthorized commercial reproduction, copying or usage which infringes on the company's rights is prohibited for both individuals and organizations. The company reserves the right to pursue legal action against violators.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

TGA Sets 2026–2027 Compliance Principles, Flags Vaping Goods as a 2026 Priority
TGA Sets 2026–2027 Compliance Principles, Flags Vaping Goods as a 2026 Priority
The Therapeutic Goods Administration (TGA) has released its Compliance Principles for 2026 and 2027.Among 12 therapeutic goods categories identified for priority compliance and enforcement activity, TGA includes vaping goods, and it plans a further review of these priorities in March 2026.
Jan.23 by 2FIRSTS.ai
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
PMI reports full-year 2025 results with net revenues of $40.6 billion and smoke-free net revenues were about $16.9 billion
Philip Morris International (PMI) released its Q4 and full-year 2025 results on February 6, 2026. PMI reported full-year net revenues of $40,648 million ($40.6 billion), reported diluted EPS of $7.26 and adjusted diluted EPS of $7.54. PMI said smoke-free net revenues were $16.9 billion and represented 41.5% of total net revenues, with smoke-free products available in 106 markets and over 43 million estimated adult consumers.
Feb.06 by 2FIRSTS.ai
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
2Firsts Flash|PMI Reports 2025 Results as Smoke-Free Products Account for 41.5% of Net Revenues
Philip Morris International reported full-year 2025 results on February 6, with smoke-free products accounting for 41.5% of adjusted net revenues, up from 38.7% a year earlier. Total net revenues rose 7.3% to $40.65 billion, while shipment volumes increased 1.4%, widening the gap between revenue and volume growth. Cigarette shipments declined as smoke-free volumes rose 12.8%, driven by heated tobacco, oral nicotine and e-vapor products. Results were released alongside a 9:00 a.m. EST webcast.
Feb.06
Hillsborough County Public Schools to install vaping detection sensors across all high schools
Hillsborough County Public Schools to install vaping detection sensors across all high schools
Hillsborough County Public Schools (HCPS) announced it will install vaping detection sensors across all high schools in Hillsborough County as part of what officials called a “proactive step” toward healthier and safer learning environments. District staff said the sensors are intended to help reduce vaping on campus, support student well-being and encourage positive behavior change.
Feb.26 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
FDA Issues Draft PMTA Guidance for Flavored E-Cigarettes, Maintaining Higher Evidence Bar for Fruit and Sweet Flavors
FDA Issues Draft PMTA Guidance for Flavored E-Cigarettes, Maintaining Higher Evidence Bar for Fruit and Sweet Flavors
The U.S. Food and Drug Administration (FDA) on March 9 released a draft guidance outlining its current thinking on premarket tobacco product applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS). The document reiterates that fruit, candy, dessert, and other sweet-flavored e-cigarettes present a “significant public health risk” to youth and therefore face a higher evidentiary burden if manufacturers seek marketing authorization.
Mar.10 by 2FIRSTS.ai